Heghine Khachatryan: The Future of Anticoagulation Beyond DOACs
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, reposted from JTH on LinkedIn, about a recent article by Holly Dobbing et al, adding:
”Beyond DOACs: The Future of Anticoagulation
The recently highlighted article in the Journal of Thrombosis and Haemostasis explores novel and experimental anticoagulant strategies beyond current DOACs — a rapidly evolving field with profound clinical implications.
While direct oral anticoagulants (DOACs) have transformed thrombosis management, significant unmet needs remain:
- Patients with high bleeding risk
- Mechanical heart valves
- Advanced renal impairment
- Antiphospholipid syndrome
- Recurrent thrombosis despite standard therapy
Emerging therapeutic targets such as Factor XI and XIa inhibitors, RNA-based approaches, and next-generation selective pathway modulation aim to provide:
- Effective thrombosis prevention
- Reduced bleeding liability
- More precise coagulation control
For clinicians working in thrombosis and hemostasis, this represents a paradigm shift — moving from broad anticoagulation toward mechanism-refined, safer antithrombotic strategies.
As we continue strengthening thrombosis care systems in Armenia and globally, staying aligned with these innovations is essential for advancing patient safety and equity in treatment access.
Highly recommended reading for hematologists, cardiologists, and clinical researchers.”
Quoting Journal of Thrombosis and Haemostasis (JTH)‘s post:
”Novel and Experimental Anticoagulant Strategies Beyond Current DOACs
Emerging anticoagulation strategies explore contact pathway inhibition, fibrin targeting, and natural anticoagulant pathway enhancement to address DOAC limitations, promising safer thrombosis treatment with reduced bleeding risks for cardiovascular disease management.”
Title: Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants
Authors: Holly Dobbing, Katherine L. Webb, Robert Ariëns
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 16, 2026, 20:25Ilham Benzidia: Leaving ISTH 2026 With New Ideas and New Collaborations
-
Jul 16, 2026, 20:23Eman Hassan: A Fantastic Platelets and Megakaryocytes Session at ISTH 2026
-
Jul 16, 2026, 20:22Sankara Nelson Noah II: Investigating the Temporal Dynamics of Platelet – Leukocyte Interactions in Early Sepsis
-
Jul 16, 2026, 20:20Joseph Pierre Aboumsallem: Paris Certainly Delivered This Week, and Not Just Because of the Heat
-
Jul 16, 2026, 19:53Louise St. Germain Bannon: The End of Congress, the Beginning of New Collaborations
-
Jul 16, 2026, 19:18Steve Humphreys: Learning From the Leading Experts at ISTH 2026
-
Jul 16, 2026, 19:02Kellie Machlus: Where Science Meets Friendship at ISTH 2026
-
Jul 16, 2026, 18:51Aaron Paul Kithcart: When Clinical Research Comes Together at ISTH 2026
-
Jul 16, 2026, 18:40Sara Buonomo: Predicting Relapse in Immune-Mediated TTP at ISTH 2026